An approach to the management of recurrent metastatic squamous cell carcinoma of the anus: A case report-Reference-Cited by-同舟云学术

An approach to the management of recurrent metastatic squamous cell carcinoma of the anus: A case report

Published:2023-06-20 Issue:1 Volume:9 Page:22-26
ISSN:2582-1318
Container-title:Journal of Case Reports and Images in Oncology
language:en
Short-container-title:J Case Rep Images Oncology

Author:

Lofters Jason¹,Elsheikh Marwa¹,Mantena Rohit²,Jhawer Minaxi³

Affiliation:

1. Department of Medicine, Englewood Hospital, Englewood, New Jersey, USA

2. Student, Bergen County Academies, Hackensack, New Jersey, USA

3. Hematology Oncology Physicians of Englewood, Englewood Hospital, Englewood, New Jersey, USA

Abstract

Introduction: Anal squamous cell carcinoma (ASCC) is an uncommon gastrointestinal cancer that is increasingly curable when diagnosed in early stages. Distant metastases are relatively uncommon. New technologies have been introduced for the early detection of disease recurrence across all solid tumors, but their role in ASCC has not been well described. We present a case of isolated metachronous metastasis to the lung from primary ASCC, without primary recurrence and the application of circulating tumor DNA (ctDNA) technology in management. Case Report: The patient is a 63-year-old female who presented with altered bowel habits, rectal bleeding and was found to have a 3×2 cm mass fixed to the anal sphincter on colonoscopy. Biopsy showed moderately differentiated invasive squamous cell carcinoma. Imaging revealed inguinal lymphadenopathy but was negative for distant metastases. She underwent definitive chemoradiotherapy without complications. Post-treatment surveillance scans were negative for residual disease or distant metastasis. Two years later, positron emission tomography (PET)/computed tomography (CT) scans revealed a 0.5 cm sub-pleural nodule which when repeated three months later grew to 0.7 cm. The nodule was then surgically resected. Histology was positive for metastatic squamous cell carcinoma, similar to the primary tumor. Given the dearth of data related to treatment in the setting of resected isolated metastatic disease we pursued ctDNA testing which was negative. Given this finding along with the clinical presentation, time to metastasis (two years) and absence of other evidence of recurrence we opted to monitor expectantly rather than administer systemic chemotherapy. Conclusion: Anal squamous cell carcinoma with metachronous distant metastasis is an unusual phenomenon. Treatment with chemotherapy in completely resected metastatic disease is controversial. Use of ctDNA technology may have a role in aiding in this complex decision making.

Publisher

Edorium Journals Pvt. Ltd.

Subject

Microbiology

Reference14 articles.

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2015), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Anal Cancer (1973–2009).

2. American Cancer Society. Cancer facts and figures 2018. Atlanta, GA: American Cancer Society; 2018.

3. Benson AB, Venook AP, Al-Hawary MM, et al. Anal carcinoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16(7):852–71.

4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER Research Data, 8 Registries, Nov 2021 Sub (1975–2019) – Linked To County Attributes – Time Dependent (1990-2019) Income/Rurality, 1969–2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.

5. Osborne MC, Maykel J, Johnson EK, Steele SR. Anal squamous cell carcinoma: An evolution in disease and management. World J Gastroenterol 2014;20(36):13052–9.